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KEY MESSAGES 
 Patient and public involvement (PPI) in research is predominantly focused 
at the level of individual research studies; however, a move toward PPI 
being embedded within the wider infrastructure of the organisation may 
maximise benefits for all involved. 
 This approach has potential to promote relationship building, generate 
more sustainable, efficient PPI practices and accelerate development of 
skills and expertise for patient partners, researchers and other stakeholder 
collaborators.  
 Organisational level PPI requires adequate resourcing, co-ordination and 
cultural change. 
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Moving beyond project specific patient and public involvement in research 
 
Grace Turner and colleagues explore patient and public involvement (PPI) in 
research and argue that developing the infrastructure for involvement at an 
organisational level can maximise benefits for all involved. 
Introduction 
Patient and public involvement (PPI) is an active partnership between patients, the 
public and researchers in the research process.(1) Patients and the public offer 
unique insights from their lived experiences which cannot be substituted by expert 
knowledge from clinicians, researchers or other specialist stakeholders. These 
insights are important to ensure research is relevant and high quality.(2) 
Furthermore, the public have a right to be involved in research which may affect 
them and, often, is publicly funded.(3) The active partnership distinguishes 
involvement activities from patient and public engagement which is the sharing of 
research, such as science festivals or newsletter articles, and people as ‘subjects’ or 
participants in research.(1) 
There has been an international drive to promote and raise the profile of PPI in 
research and for PPI to change how research is designed and conducted.(4, 5) 
Recently, an international network for PPI in health and social care research was 
established which aims to promote and advance PPI through a global partnership.(6) 
Major funders of healthcare research increasingly expect evidence of 
comprehensive, meaningful PPI in the development of grant applications and 
planned PPI within the proposed project.(4, 5) For example, in the United Kingdom, 
the National Institute for Health Research (NIHR) have PPI policies within their 
research and grant committees and fund INVOLVE, a national advisory group to 
advance PPI.(4, 7) Similarly, in the United States, the Patient Centred Outcomes 
Research Institute (PCORI) promotes patient input to guide research questions and 
supports active involvement from patients in reviewing applications, sitting on 
advisory committees and providing feedback on policy documents.(5) Funder 
requirements and expectations have been important drivers for the increase in 
number of research studies involving patient partners in the planning and delivery of 
research.(2) 
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Research strategy and infrastructure 
Currently, PPI in research is predominantly focused on specific aspects of individual 
research studies such as the initial study set-up, data analysis, report writing and 
dissemination.(8) Although major funders integrate PPI within their broader 
infrastructure, PPI within organisations, such as academic research centres, is often 
ad hoc with different projects conducting PPI independently from each other.(9) This 
‘siloed’ approach has been identified as a barrier to effective PPI and resulted in a 
call for more collaborative practices.(9) An alternative method is for organisations to 
take a broader perspective whereby PPI moves beyond project specific activities and 
is embedded within the wider infrastructure of the organisation. Research 
organisations should have a public involvement strategy at an organisational level, 
which patient and the public contribute to and regularly review. To ensure patient 
priorities, perspectives and unique skillsets are incorporated within the organisational 
research strategy, public contributors could be included on strategy groups or 
executive committees and contribute to research prioritisation and major 
infrastructure bids. (Box 1). The latest NIHR INVOLVE Standards for Involvement 
includes indicators for organisations as well as individuals and organisations.(10) 
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BOX 1: Embedding PPI in an academic research centre 
 The Centre for Patient Reported Outcomes Research (CPROR) is a world-
leading centre for Patient Reported Outcomes (PRO) research. PROs 
capture the patients’ perspective; therefore, it is essential to have the 
patients’ voice at the heart of all our research activities.  
 Patients and members of the public have been involved from the start 
through contributing to Centre Strategy and actively participating in the 
Centre launch. 
 Patient/public partners are part of the research team and receive training 
and support and participate in activities in line with academic staff including 
inductions (tailored appropriately); assessment of training needs; 
representation on relevant management groups; attending events (such as 
conferences); participation in all activities from research strategy to 
dissemination; and inclusion in social activities, such as Christmas meals. 
 We have integrated PPI within the CPROR infrastructure through a variety 
of different approaches, including: representatives on the Executive 
Committee; User Advisory Groups for individual research projects; co-
production of training materials; co-hosting a ‘Patients Included’ accredited 
conference (Box 2); and collaboration with PPI experts from NIHR 
infrastructure to share knowledge and best practice. 
 We promote capacity building through our online training resource 
PROLearn, which includes a free online module for patient advocates 
involved in the co-design of PROs research/reviewing research protocols. 
PROLearn was co-produced with patient partners. 
(https://www.birmingham.ac.uk/Prolearn) 
 We embed PPI within the Centre’s research throughout the research cycle 
from research prioritisation and identifying new research topics, to 
dissemination including co-authored publications.  
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BOX 2: Patients included accredited conference 
 What we did: Public contributors were at the heart of planning and 
delivering the UK and Ireland PROMS 2018 Conference (Birmingham, UK), 
which received the Patients Included Chatermark accreditation.  
 Public Involvement in planning the event: The Conference Organising 
Committee included a public contributor and a PPI Lead who were involved 
in planning and delivering the event. Members of the public were involved 
in reviewing abstracts. 
 Public Involvement at the event: 10 bursaries were offered for patients 
and the public. Public contributors who attended were supported by the 
PPI lead prior to the event, and received information on what to expect on 
the day, had catering to specific needs and could visit a dedicated stand on 
the day for all delegates where people could ask questions/receive 
information.  
 Impact of public involvement: 
o Patient conference co-chair and presentations from public 
contributors ensured that priorities of patients were a focus for the 
day. 
o Panel discussions included perspectives from patients on the 
relevance of research areas, impact of research to improve health 
outcomes and future directions for research.  
o Public perspectives were included in decisions to award prizes 
including a prize for the best innovation in public involvement in 
PROMs research. 
o Public contributors were involved in writing summaries of the 
Conference 
 Article in the Journal of Patient Reported Outcomes 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297120/ 
 Blog for the BMJ opinion 
https://blogs.bmj.com/bmj/2018/08/23/richard-lehman-and-
magdalena-skrybant-a-day-at-the-proms/ 
o Successful inclusion of public contributors has ensured that future 
PROMs Conferences will involve public contributors in 
planning/delivering the event.  
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Benefits of an organisational level approach  
Embedding PPI at an organisational level facilitates opportunities for shared learning 
across different projects and accelerated skill development, for both patient partners 
and academic researchers. Developing connections with PPI experts, such as PPI 
leads, within the organisation and wider research infrastructures, enables direct 
access to advice and guidance, and facilitates sharing of best practice and 
knowledge, such as the latest guidance and standards. In turn, organisations may 
develop their own standards for PPI based on their growing experience and 
expertise which enhances the conduct of future PPI activities and creates continuity 
for long-term patient partners. 
Relationships develop over time; therefore, organisational level approaches to PPI 
may facilitate building and sustaining relationships with patients and the public, 
which has been identified as a key enabler to meaningful PPI.(11) Models of PPI 
which incorporate relationship building have greater impact than one-off PPI 
activities.(2) Furthermore, such an approach may offer unique, unanticipated 
opportunities for research collaboration and co-production (Box 3). Evidence shows 
involvement in research has benefits for patients and the public, including: giving 
people a purpose; gaining new knowledge about their condition(s); understanding 
more about research and the latest evidence; opportunities to use existing skills and 
develop new skills; building confidence; and opportunities to meet other people and 
gain additional support (Box 4).(3)  
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BOX 3: Thinking outside the box- innovative patient partner collaborations  
Patient partner, Gary Price, is employed as an International Product Manager at 
the company ERIKS, which provides customised, automated and innovative 
engineering solutions for design, manufacturing and production processes.  
Through discussions with Gary it became apparent that there was a clear 
opportunity to learn from ERIKS and consider how cutting edge process 
management, condition monitoring and use of cloud based technology in an 
engineering setting could be applied to healthcare.   MRC Proximity to Discovery 
funding was secured to facilitate research group members to visit ERIKS 
European Innovation Centre in Rotterdam, fostering multidisciplinary 
collaboration, sharing of good practice and directly informing our research. 
 
Group pictures taken after a tour of the ERIKS manufacturing plant to see first-
hand the processes discussed earlier.  
Picture 1, Left to right are: Wouter Siepman (Formerly ERIKS); Derek Kyte, Lee Aiyegbusi, Mel 
Calvert (CPROR members); Gary Price (ERIKS staff and CPROR patient partner) 
Picture 2, Left to right are: Wouter Siepman (Formerly ERIKS); Mel Calvert, Lee Aiyegbusi, Derek 
Kyte (CPROR members) 
(Permissions were granted by all for the pictures to be taken and used in subsequent publications. 
The pictures were uploaded to and are currently in public domain on the Twitter website.) 
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BOX 4: Experience of PPI from CPROR patient partner Gary Price 
“Due to my profession as an engineer, I engaged in using patient reported 
outcomes when I was diagnosed with serious illness. As it was going to be a long 
process of intense treatment and (hopefully) recovery, I decided to create my own 
list of outcomes for physical, mental and wellbeing, then monitor myself to see 
how the drugs were affecting me long term. Each day I would rate myself adding 
in my blood test results along the way. I would send these to the clinicians every 
few days. 
At first the team of clinicians that were treating me would have a bit of a laugh 
with me about my charts and graphs, but within a few weeks based on my 
outcomes they were using my results to discuss with me how to continue the 
treatment. This in turn meant they could see from a patient’s point of view and 
feeling, exactly what was going on, there were no surprises, no reason to see me 
for the sake of seeing me and more importantly I could continue receiving the high 
doses of drugs that saved my life.   
Two years after my recovery, based on my recent illness experience and how I 
had dealt with it, the consultant who treated me asked if I would consider 
contributing to PPI for a cancer trial. Through this I met Prof Calvert who was 
developing a proposal for a new research centre for patient reported outcomes 
research and I was invited to contribute to the centre strategy. After initial 
meetings and understanding of what this involved and how it will help patients and 
clinicians in future, I gladly accepted the role and have been involved in the centre 
ever since. Four years on and I consider myself very fortunate to be a key part of 
a team that has the patient at the core of its strategy. I have been able to see how 
more and more health sectors that the CPROR engage with are realising the 
advantage of having a formal and structured PPI, introducing a new dynamic to 
how patients are viewed and treated. I have been able to see at root level how 
patients are involved from concept of trials to delivery and how the clinicians value 
their input.    
Finally: There are other advantages that sometimes can help play a part with PPI. 
Take the case of myself, as part of my day to day job I have gained a lot of 
experience within condition monitoring and asset management industry. From this 
I have been able to channel a lot of my knowledge into helping and contributing to 
the research that the CPROR is doing on remote monitoring, data collection and 
analysis. I believe I am a good example of PPI where a patient not only has 
experience of a serious illness but also has experience of the work that the team 
is doing.” 
Gary Price, CPROR patient partner          
 
12 
 
 
Challenges and facilitators 
Embedding PPI in organisations is resource intensive and requires adequate 
funding, planning and time allocation (Box 5). Public contributors need to be 
supported in their involvement and should receive relevant training and 
reimbursement for their expenses and time commitment. Expenses directly incurred 
as a result of participating in research should be covered for clinicians and other 
collaborators and refreshments provided as required. Consideration should also be 
given to communication with public contributors, collection and sharing of feedback 
on public involvement, and evaluation and reporting of activities. Individual research 
projects should be appropriately costed for PPI training and activities.(12, 13) 
However, a challenge is the lack of funding opportunities for organisational level PPI, 
which is not associated with  a specific research project, particularly in University 
settings.  
In the past, clinical research was often based on research objectives and agendas of 
clinicians and researchers. The studies were mostly designed, conducted and 
disseminated by clinicians and researchers with little or no input from patients or the 
general public.(2) One of the issues with this traditional approach was that such 
objectives and outcomes may not match those prioritised highly by patients who are 
supposed to benefit from research studies thus potentially limiting the usefulness 
and impact of research findings.(2) PPI provides the opportunity for patients, their 
families, carers and the general public to become co-members of the research team, 
participate and contribute to research alongside clinicians and researchers. 
Widening involvement in research this way, particularly to include under-represented 
voices from minority and hard to reach communities, is a well-recognised 
challenge.(2) Embedding PPI at an organisational level has potential to accentuate a 
lack of diversity as the nature of organisation level activities may unintentionally 
create bias in recruitment of patient partners. For example, attending an 
organisation’s executive committee meeting may not be possible for public 
contributors with work/ carer responsibilities and individuals from low socioeconomic 
backgrounds may find these meetings intimidating. Therefore, it is important that 
organisations are aware of these risks and take steps to actively address diversity. 
These may involve: developing relationships with local communities; widely 
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advertising involvement opportunities; provision of additional training and support for 
public contributors; and ensuring chairs of meetings have the skills to involve public 
contributors in discussions and decision making.(10) In addition, it is important to 
have varied, flexible opportunities for involvement (beyond formal meeting) and 
ability to adapt to people’s changing circumstances and changes how much they 
want to contribute. 
Although the proposed embedded model of PPI suggests all team members are 
actively engaged in PPI, having a person(s) who co-ordinates and is responsible for 
PPI can be beneficial to drive PPI initiatives, maintain momentum, monitor 
involvement strategies and outcomes, and be a named point of contact.(2) However, 
there is a danger that research teams become reliant on the PPI lead which may 
hinder team engagement with PPI and shared learning.(2) Ongoing, regular 
communication with public contributors, both formal and informal contact, is critical 
for building and sustaining relationships.(12) 
Support from senior leadership is important to promote a culture of PPI as standard 
practice and to ensure organisations have a public involvement strategy. Cultural 
changes are required to embed PPI at an organisational level and to create an 
environment where PPI is valued by researchers and viewed as the norm rather than 
an added extra.(9) Involving patient partners in research should be done instinctively 
by all team members and patient partners should be regarded as integral members 
of the research team (Box 1).  
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BOX 5: Tips for successful partnerships 
Changing culture  
 Team effort – advocacy throughout institution from student and early 
career researcher groups to senior management committees 
 Recognition for staff who lead/ facilitate public involvement activities 
 Acknowledgement of patient partners are team members 
 Involve patient partners in all team activities including social events 
 Arrange an induction for patient partners (similar to a new member of staff)  
 Demonstrate input is valued (honoraria, thanking people, listening and 
responding to ideas)  
Practical considerations 
 Accessibility and travel 
 Reimbursement 
 Training and support for patients, public and researchers 
 Flexible working arrangements  
 Develop processes to pay honoraria 
 Have named contact for public contributors 
Communication 
 Explain the context of the research, such as rationale, timelines and 
relevance to clinical care and patient 
 Listen to views and make necessary changes 
 Establish roles and ground-rules 
 Manage expectations 
 Address any concerns 
 Maintain regular contact  
 Identify optimal mode/preferences/frequency of communication 
Measure impact 
 Consider use of key performance indicators – for example involvement of 
patients and the public on committees, grant applications, publications 
 Use guidance for reporting patient and public involvement version 2 
(GRIPP2) as a framework to report PPI. The checklist was developed in 
order to address inconsistent reporting by assisting researchers, patients, 
carers, and the public with the reporting of PPI activities so as to improve 
the quality, consistency, and transparency of reports. 
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Measuring the impact of PPI 
PPI has the potential to positively impact on research at multiple levels, promoting 
quality and relevance of research and benefitting the wider research system.(11) 
Impact should be assessed by measuring pre-determined key performance 
indicators linked to research outcomes and processes(14) through qualitative and/or 
quantitative methods.(3) Individual level performance indicators could include 
acquisition of new skills and knowledge for the PPI contributors and better 
understanding of the research field from a patient perspective for the research 
team.(11) Research quality indicators could include PPI in research prioritisation;(15) 
contributions to research design and methods;(16) collaborations on grant 
applications;(17, 18) and dissemination of findings via co-authorship on publications 
and presentations at conferences.(3) Wider research system impact could be 
measured by assessing influence on advocacy and accountability in terms of the 
allocation of research resources.(14)  
There is drive to capture key performance indicators for individual research projects; 
however, it is also important to document these indicators at an organisational level 
and think beyond project-specific objectives. The use of the GRIPP2 checklist(13) to 
report PPI activities and utilisation of the newly developed Cost and Consequences 
Framework(19) may enhance transparency and accuracy in the reporting of positive 
and negative impacts. Furthermore, consideration should be given to capturing ‘soft’ 
outcomes, such as relationship building, which are often more difficult to measure. 
Conclusion 
There is a need to move away from patients and the public only being involved in 
individual research projects and move towards models where PPI is considered at 
an organisational level and patient partners are valued team members. This 
approach has potential to promote relationship building, generate more sustainable, 
efficient PPI practices and accelerate development of skills and expertise for patient 
partners, researchers and other stakeholder collaborators. However, it requires 
adequate resourcing, co-ordination and cultural change.  
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